Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
- Conditions
- LymphomaNonneoplastic Condition
- Interventions
- Genetic: polymerase chain reactionOther: laboratory biomarker analysis
- Registration Number
- NCT00981097
- Lead Sponsor
- AIDS Malignancy Consortium
- Brief Summary
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood and tissue samples from patients with aggressive non-Hodgkin B-cell lymphoma or Hodgkin lymphoma.
- Detailed Description
OBJECTIVES:
Primary
* To estimate the proportion of patients with diffuse large B-cell/immunoblastic and Burkitt histologies with elevated serum free light chains (FLC).
* To estimate the proportion of patients with Hodgkin lymphoma with clonal immunoglobulin (Ig) DNA detection in the plasma.
Secondary
* To estimate the agreement between the detection of a monoclonal Ig DNA spike in plasma and the detection of a monoclonal DNA spike in tumor tissue.
* To estimate the agreement between the fragment length of a spike in tumor tissue and the fragment length of the spike in plasma.
* To estimate the detection rate of elevated FLC in each histology, including diffuse large B-cell/immunoblastic and Burkitt lymphoma.
* To estimate the detection rate of clonal Ig DNA in each histology, including diffuse large B-cell/immunoblastic, Burkitt lymphoma, and Hodgkin lymphoma.
* To analyze clinical and pathologic correlates of detection by the serum/plasma tests: disease subtype, stage of disease, disease bulk, lactate dehydrogenase, and Ki-67 index.
* To estimate the detection rate of clonotypic B-cells in peripheral blood mononuclear cells from patients with Hodgkin lymphoma.
OUTLINE: This is a multicenter study.
Blood and tissue samples collected at the time of diagnosis are analyzed for serum free light chain and clonal immunoglobulin (Ig) DNA rearrangements and circulating clonotypic B-cells via PCR.
PROJECTED ACCRUAL: A total of 50 patients (25 with diffuse large B-cell/immunoblastic histologies, 15 with Burkitt lymphoma, and 10 with Hodgkin lymphoma) will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 52
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Specimen Collection laboratory biomarker analysis Subjects with a diagnosis of HIV and an untreated aggressive B-cell lymphoma. Specimen Collection polymerase chain reaction Subjects with a diagnosis of HIV and an untreated aggressive B-cell lymphoma.
- Primary Outcome Measures
Name Time Method Proportion of patients with Hodgkin lymphoma clonal immunoglobulin (Ig) DNA detection in the plasma Study entry Proportion of patients with diffuse large B-cell/immunoblastic and Burkitt histologies with elevated serum free light chains (FLC) Study entry
- Secondary Outcome Measures
Name Time Method Detection rate of clonotypic B cells in peripheral blood mononuclear cells from patients with Hodgkin lymphoma Study entry Analysis of the clinical and pathologic correlates of detection by the serum/plasma tests: disease subtype, stage of disease, disease bulk, lactate dehydrogenase, and Ki67 index Study entry Detection rate of clonal Ig DNA in each histology, including diffuse large B-cell/immunoblastic, Burkitt lymphoma, and Hodgkin lymphoma Study entry Agreement between the detection of a monoclonal Ig DNA spike in plasma and the detection of a monoclonal DNA spike in tumor tissue Study entry Agreement between the fragment length of a spike in tumor tissue and the fragment length of the spike in plasma Study entry Detection rate of elevated FLC in each histology, including diffuse large B-cell/immunoblastic and Burkitt lymphoma Study entry
Trial Locations
- Locations (16)
Boston University Cancer Research Center
🇺🇸Boston, Massachusetts, United States
Thomas Street Health Center
🇺🇸Houston, Texas, United States
Benaroya Research Institute at Virginia Mason Medical Center
🇺🇸Seattle, Washington, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
🇺🇸Baltimore, Maryland, United States
Rebecca and John Moores UCSD Cancer Center
🇺🇸La Jolla, California, United States
Mallinckrodt Institute of Radiology at Washington University Medical Center
🇺🇸Saint Louis, Missouri, United States
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
🇺🇸Saint Louis, Missouri, United States
UNC Hospitals, The University of North Carolina at Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States
UCLA Clinical AIDS Research and Education (CARE) Center
🇺🇸Los Angeles, California, United States
Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States
University of Miami
🇺🇸Miami, Florida, United States
Baylor University Medical Center - Houston
🇺🇸Houston, Texas, United States
UCSF Helen Diller Family Comprehensive Cancer Center
🇺🇸San Francisco, California, United States
University of California at Davis Center for Aids Research and Education Services
🇺🇸Sacramento, California, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States